Time filter

Source Type

Gutierrez-Rojas L.,University of Granada | Azanza J.R.,University of Navarra | Bernardo M.,Institute dlnvestigacions Biomediques August Pi i Sunyer IDIBAPS | Bernardo M.,Research Center Biomedica En Red Of Salud Mental Cibersam | And 5 more authors.
Actas Espanolas de Psiquiatria | Year: 2014

Introduction: Metabolic syndrome (MS) (visceral obesity, dyslipidemia, hyperglycemia, and hypertension), has become one of the major public-health challenges worldwide. Patients with schizophrenia are more likely to suffer from MS than the general population. Objective: The primary aim of this study was to analyze the prevalence of MS in Spanish patients with schizophrenia and overweight and to compare the best method to calculate the MS prevalence in this population. A secondary aim of the CRESSOB study was to determine whether the presence of the metabolic syndrome (MS) is associated or not with clinical remission of schizophrenia. Methods: The Control of Metabolic and Cardiovascular Risk in Patients with Schizophrenia and Overweight (CRESSOB) study is a 12-month, prospective, naturalistic study including 110 community mental health clinics selected at random. Each site enrolled four consecutive patients with a diagnosis of schizophrenia, according to DSM-IV TR criteria, and who were overweight (Body Mass Index (BMI) >25 kg/m2). To assess the prevalence of MS we analyzed the baseline results of the CRESSOB study. The National Cholesterol Education Program (NCEP-ATP III), the International Diabetes Federation (IDF) and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) definitions were used to establish the presence of MS. The Positive and Negative Syndrome Scale (PANSS) was used to determine the percentage of patients in remission. Psychosocial functioning was measured by the Global Assessment of Functioning (GAF) scale. Results: A total of 391 patients were enrolled in the study (mean age 40.5 years, 63.8% men). 75.9% of the patients did not meet criteria for remission, using the selected PANSS items. The mean GAF score was 52.7 (Standard Deviation (SD) 15.4). Overall, 59.0% of males and 58.3% of females fulfilled the NCEP-ATP III criteria, 71.1% of males and 65.8% of females fulfilled the IDF criteria and 70.1% of males and 65.1% of females fulfilled the AHA/NHLBI criteria. The patients who fulfilled remission criteria were younger, had a lower BMI, and a higher GAF score. Conclusions: MS is highly prevalent in Spanish patients with schizophrenia who are overweight. Given that metabolic syndrome is an important risk factor for cardiovascular disease, these patients should receive appropriate clinical monitoring for this syndrome.


Mendes-Braz M.,University of Sao Paulo | Elias-Miro M.,Institute dLnvestigacions Biomediques August Pi i Sunyer IDIBAPS | Jimenez-Castro M.B.,Institute dLnvestigacions Biomediques August Pi i Sunyer IDIBAPS | Casillas-Ramirez A.,Institute dLnvestigacions Biomediques August Pi i Sunyer IDIBAPS | And 3 more authors.
Journal of Biomedicine and Biotechnology | Year: 2012

The present review focuses on the numerous experimental models used to study the complexity of hepatic ischemia/reperfusion (I/R) injury. Although experimental models of hepatic I/R injury represent a compromise between the clinical reality and experimental simplification, the clinical transfer of experimental results is problematic because of anatomical and physiological differences and the inevitable simplification of experimental work. In this review, the strengths and limitations of the various models of hepatic I/R are discussed. Several strategies to protect the liver from I/R injury have been developed in animal models and, some of these, might find their way into clinical practice. We also attempt to highlight the fact that the mechanisms responsible for hepatic I/R injury depend on the experimental model used, and therefore the therapeutic strategies also differ according to the model used. Thus, the choice of model must therefore be adapted to the clinical question being answered. Copyright © 2012 M. Mendes-Braz et al.


Langdon C.,Hospital Clfnic | Langdon C.,Institute Dlnvestigacions Biomediques August Pi I Sunyer Idibaps | Mullol J.,Hospital Clfnic | Mullol J.,Institute Dlnvestigacions Biomediques August Pi I Sunyer Idibaps | Mullol J.,Center for Biomedical Research in Respiratory Diseases
Journal of Asthma and Allergy | Year: 2016

Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often have coex­isting asthma under the concept of “United Airway Disease”, being the combination of both diseases, which is one of the most challenging phenotypes to treat. Although clinicians have recognized this difficult-to-treat phenotype for many years, it remained poorly characterized. There is increasing epidemiological evidence linking chronic rhinosinusitis and asthma, but a good understanding of the pathophysiology and the combined management is still lacking. Bronchial asthma is more prevalent in patients who suffer chronic rhinosinusitis, while asth­matic patients have a greater prevalence of CRSwNP than patients without asthma. The effect of CRSwNP treatment, whether medical or surgical, in asthma is today less controversial after some studies have shown improvement of asthma after medical and/or surgical treatment of CRSwNP. However, direct comparisons between surgical and medical treatments are limited. Further randomized clinical trials are, however, still needed to better understand the management when both asthma and CRSwNP occur together. This review aims at summarizing the prevalence, impact, and management challenges regarding both asthma and CRSwNP. © 2016 Langdon and Mullol.

Loading Institute dlnvestigacions Biomediques August Pi i Sunyer IDIBAPS collaborators
Loading Institute dlnvestigacions Biomediques August Pi i Sunyer IDIBAPS collaborators